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Abstract  
 
An Australian estuarine isolate of Penicillium sp. MST-MF667 yielded three novel 
tetrapeptides named the bilaids with an unusual alternating LDLD chirality. Given their 
resemblance to known short peptide opioid agonists we elucidated that they were weak (Ki 
low M) μ-opioid agonists which led to the design of bilorphin, a potent and selective μ-
opioid receptor (MOPr) agonist (Ki 1.1 nM). In sharp contrast to all natural product opioid 
peptides that efficaciously recruit β-arrestin, bilorphin is G-protein biased, weakly 
phosphorylating the MOPr and marginally recruiting β-arrestin, with no receptor 
internalization. Importantly, bilorphin exhibits a similar G-protein bias to oliceridine, a small 
non-peptide with improved overdose safety. Molecular dynamics simulations of bilorphin 
and the strongly arrestin-biased endomorphin-2 with the MOPr indicate distinct receptor 
interactions and receptor conformations that could underlie their large differences in bias. 
Whereas bilorphin is systemically inactive, a glycosylated analog, bilactorphin, is orally 
active with similar in vivo potency to morphine. Bilorphin is both a unique molecular tool 
that enhances understanding of MOPr biased signaling, and a promising new lead in the 
development of next generation analgesics. 
 
Significance  
Agonists of the μ-opioid receptor (MOPr) are currently the gold standard for pain treatment. 
However, their therapeutic usage is greatly limited by side effects including respiratory 
depression, constipation, tolerance and dependence. Functionally selective MOPr agonists 
that mediate their effects preferentially through G-proteins rather than β-arrestin signaling are 
believed to produce fewer side effects. Here we present the discovery of three unusual 
tetrapeptides with a unique stereochemical arrangement of hydrophobic amino acids from an 
Australian estuarine isolate of Penicillium species. Building on these natural templates we 
developed bilorphin, a potent and selective highly G-protein biased agonist of the MOPr. 
Further, through the addition of a simple sugar moiety we generated bilactorphin that is an 
effective analgesic in vivo. 
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Introduction 
Developing ligands that target G protein-coupled receptors (GPCRs) in multiple functional 
states has attracted great interest, particularly with increasing knowledge of GPCR structure.
1-
3
 These novel ligands are expected to underpin the development of agonists with superior 
pharmaceutically relevant properties, including biased receptor signaling,
4,5
 whereby one 
downstream signaling pathway is favored over another. For example, biased agonists that 
signal by differentially recruiting G-proteins over β-arrestin to μ-opioid receptor (MOPr), 
could deliver better analgesics, based on the view that downregulating β-arrestin recruitment 
diminishes adverse side effects.
4,6-8
 Exploiting this concept, the G-protein-biased MOPr 
agonist oliceridine (TRV130) is a potent analgesic in rodents, with lower respiratory 
depression and gastrointestinal dysfunction compared to morphine.
7
 Indeed, human clinical 
trials of oliceridine show reduced respiratory impairment compared to morphine administered 
at equi-analgesic doses.
9
 Reduced respiratory depression delivers improved safety, potentially 
reducing the burden of opioid overdoses, now at epidemic proportions in many 
jurisdictions.
10
  
 
Bioactive peptides display great promise for their novel pharmacological properties.
11
 Since 
the discovery of the relatively non-selective mammalian opioid peptides, the enkephalins, 
other endogenous mammalian ligands, including the tetrapeptide endomorphins that target 
the MOPr with high selectivity over the related κ-opioid (KOPr) and δ-opioid (DOPr) 
subtypes, have been found.
12,13
 Natural peptide agonists containing a D-Ala in the second 
position formed by a post-translational modification isolated from frog skin, dermorphin and 
deltorphin II, selectively target MOPr and DOPr, respectively.
14
 Similar synthetic 
modifications have yielded enhanced biological stability and receptor selectivity. For 
example, introduction of D-Ala stabilizes the enkephalins to proteolysis and further 
substitutions yield highly stable, selective MOPr agonists such as DAMGO ([D-Ala2, N-
MePhe4, Gly5-ol]-enkephalin).
15
 However, to our knowledge, all endogenous opioid peptides 
acting on MOPr robustly recruit arrestins and produce MOPr internalization.
16-19
 Here we 
report the discovery of three tetrapeptides, bilaids A-C (Fig. 1 a-c [1a-3a]), from an 
Australian estuarine isolate of Penicillium sp. MST-MF667 (initially reported as P. bilaii
20
 - 
maximum likelihood tree presented in SI Appendix Fig. S1). Discovery of the bilaids, which 
resemble known opioid peptides but featuring an unusual alternating sequence of antipodal 
amino acids (LDLD), led to our design of bilorphin (3c), a new MOPr agonist, with G-protein 
signaling bias similar to oliceridine. Bilorphin adopts a distinct conformational shape and 
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intermolecular interactions in MD simulations of the bilorphin-MOPr complex, consistent 
with predicted G-protein bias at related GPCRs. Together with its in vitro and in vivo activity 
we demonstrate that bilorphin provides a scaffold for the development of stable, orally active 
opioid peptides that are biased towards G-protein signaling (3g). 
 
Results 
To date the major opioid peptide families have only been detected in vertebrates.
21
 Through a 
broader screening program we now report the discovery of three closely related novel 
tetrapeptides (Fig. 1), bilaids A (1a, FvVf-OH), B (2a, FvVy-OH) and C (3a, YvVf-OH), 
from the Australian estuarine-derived Penicillium sp. MST-MF667. Solvent extracts of 
cultivations of MST-MF667 were subjected to solvent partition followed by reversed-phase 
HPLC to yield 1a (0.15%), as well as traces of 2a (0.0018%) and 3a (0.0008%) (Fig. 1). The 
chemical structures for 1a-3a, which resemble opioid peptides albeit with a unique, 
alternating LDLD amino acid configuration, were identified by spectroscopic analyses, 
chemical derivatization and degradation, and Marfey's analysis and total synthesis. In 
addition to synthesizing 1a-3a we prepared and screened a series of related analogues for 
inhibition of forskolin-induced cAMP formation in HEK cells expressing the human MOPr 
(hMOPr) (SI Appendix Table S1). Five hits determined to be active at a concentration of 10 
µM were tested for competitive binding against the hMOPr agonist [
3
H]DAMGO. Bilaid C 
(3a) bound with the highest affinity at the hMOPr (Ki = 210 nM, Fig. 2A, SI Appendix 
Table S1), consistent with the requirement for a Tyr moiety in the majority of peptide ligands 
targeting opioid receptors.
24
  Bilaid A (1a) showed more modest affinity (Ki = 3.1 µM) that 
was improved 4-fold through C-terminal amidation (Ki = 0.75 µM, 1e), prompting us to 
apply this modification to further analogs. Analogs of bilaid A having a DLDL (1b, 1f), 
LLDD (1c, 1g), DDLL (1d) or LLLL (1h) configuration were generally inactive, with the 
exception of FVVF-NH2 (1h) which weakly inhibited cAMP formation at 10 µM. These 
findings are consistent with previous SAR studies which revealed that having L-amino acids 
in position 2, other than those that are Nα-alkylated (e.g. L-Pro), reduce opioid agonist 
activity,
22
 as do D-amino acids in position 1.
23
 Other bilaid analogues showed no MOPr 
activity at 10 µM.  
 
C-terminal amidation of bilaid C (3b, Fig. 2A, SI Appendix Table S1) improved hMOPr 
affinity (Ki = 93 nM), consistent with the increased binding of 1e over 1a. Dimethylation of 
the N-terminal tyrosine residue (3c) resulted in significantly increased potency (Ki = 1.1 nM), 
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as has been observed for other opioid peptides. 
25
 This compound, which we name bilorphin, 
bound with nearly 200-fold selectivity for hMOPr over hDOPr (Ki = 190 nM) and 700-fold 
selectivity over hKOPr (Ki = 770 nM) (Fig. 2A, SI Appendix Table S1).  
 
To assess functional activity of bilorphin, patch-clamp recordings of G-protein activated, 
inwardly rectifying potassium channel (GIRK) currents were made in rat locus coeruleus 
(LC) neurons, which natively express MOPr but not DOPr or KOPr.
26
 Bilorphin acted as an 
agonist with potency greater than morphine. Its actions were completely reversed by the 
highly MOPr selective antagonist CTAP
27
 (n = 9, Fig. 2B,C, SI Appendix Table S1) 
establishing that bilorphin does not act on the closely related nociceptin or somatostatin 
receptors expressed by LC neurons.
28
 The native peptide, Bilaid C, was 14-fold weaker than 
morphine in the same assay system.
29
 Bilaid C analogs with an acetylated N-terminus (3d), or 
containing all L-amino acids (3e and 3f), were inactive in LC neurons at 10 - 30 µM, 
confirming the importance of a free N-terminus and the native LDLD motif for maintaining 
MOPr activity (SI Appendix Table S1).  
 
The relative potency and intrinsic efficacy of bilorphin in signaling pathways was examined 
in AtT20 cells stably expressing FLAG tagged mouse MOPr (mMOPr) to enable bias 
analysis (Fig. 2C, E).  To reliably determine the relative intrinsic efficacy of bilorphin to 
activate G-proteins (GGIRK), we partially, irreversibly inactivated receptors to reduce the 
maximum response to the high efficacy natural agonist, Methionine5-enkephalin (Met-enk), 
to 80% of that produced by somatostatin acting on native SST receptors in the same cells 
(Fig. 2C, E). Maximal activation of SST receptors normally produces a GGIRK increase 
equivalent to a maximal activation of MOPr.
30
 Under these conditions, bilorphin, morphine 
and endomorphin-2 all displayed similar maximal responses. All agonists displayed similar 
potencies in the brain slice and cell assay, with the exception of met-enk, the reduced potency 
of which in brain slices is known to result from its degradation by peptidases.
31
 As expected 
from brain slice experiments, all three opioids were moderately efficacious but less so than 
Met-enk (Fig. 2E, SI Appendix Fig. S2A). In contrast, the G-protein biased, small molecule 
agonist oliceridine, activated GGIRK significantly less efficaciously than either morphine or 
bilorphin (Fig. 2E). 
 
MOPr C-terminal phosphorylation, β-arrestin recruitment and internalization are thought to 
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contribute to on-target opioid analgesic side effects so that G-protein biased opioids that 
avoid β-arrestin signaling should show an improved side effect profile.4,7,8 We therefore 
assayed the activity of bilorphin for inducing C-terminal phosphorylation, β-arrestin 
recruitment and MOPr internalization in the same AtT20 cell line. Agonist-induced 
phosphorylation of residue serine 375 (Ser375) drives β-arrestin recruitment and 
internalization.
32
 We determined bilorphin-induced phosphoserine Ser375 (pSer375)  
phosphorylation using a phosphosite specific antibody (Fig. 3A, D).
33
 Surprisingly, and 
unlike other opioid peptides,
19,32,33
 bilorphin produced low levels of pSer375 (30 M, Fig. 
3A, D, SI Appendix Fig. S2B), which appeared less than that produced by morphine, but this 
difference was not statistically significant (SI Appendix Fig. S2B). Using MOPr-luciferase 
and β-arrestin2-YFP constructs, a BRET assay was performed to determine β-arrestin 2 
recruitment (Fig. 3B, D).
34
 Similar to phosphorylation, saturating concentrations of bilorphin 
induced very low levels of BRET efficiency, significantly less than that produced by 
morphine (30 μM, Fig. 3B). MOPr internalization was assessed immunocytochemically after 
30 minutes of agonist treatment (Fig. 3C, D). Bilorphin produced almost no detectable 
internalization of MOPr, compared to low levels induced by morphine and robust 
internalization driven by both endomorphin-2 and Met-enk (Fig. 3D). In summary, when 
normalized to the maximum response to Met-enk in each pathway, bilorphin displayed 
similar maximal G-protein efficacy to morphine with progressive reduction in relative 
efficacy across pathways from Ser375 phosphorylation, β-arrestin recruitment to 
internalization (Fig. 3D), suggesting that bilorphin is a G-protein biased opioid. 
 
Operational analysis, the de facto standard for quantifying biased signaling,
35,36
 suggests that 
bilorphin is G-protein biased relative to morphine (SI Appendix Fig. S2) but this requires 
accurate determination of EC50, which was impractical for bilorphin due to its very low 
internalization efficacy (SI Appendix Fig. S2).
35
 Calculation of relative efficacy from 
maximum response in each pathway provides a complementary estimate of bias in signaling 
assays where all agonists are partial.
36,37
 This approach (SI Appendix Fig. S2, Table S2) 
substantiated the G-protein bias of bilorphin relative to morphine.
19,34
 To further substantiate 
the bias of bilorphin compared with morphine and the established G-protein biased agonist 
oliceridine, both of which produce very little internalization, we enhanced internalization by 
overexpressing GRK2-YFP and β-arrestin 2-HA.38 In GRK2 positive cells, morphine, 
oliceridine and bilorphin all produced clear internalization signals (SI Appendix Fig. S3A). 
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Quantification shows that even under these amplified conditions, bilorphin induces similar 
MOPr internalization to oliceridine but significantly less than morphine at saturating 
concentrations (SI Appendix Fig. S3B, C). Calculation of bias relative to morphine with the 
Max method suggests that bilorphin exhibits significant G-protein bias that is similar to 
oliceridine, further establishing it to be a novel G-protein biased opioid (SI Appendix Fig. 
S3C). 
 
The widely accepted mechanism for ligand bias is the stabilization of distinct GPCR 
conformations that favour coupling to different intracellular proteins.
39
 However, how such 
biased agonists interact with the receptor binding pocket and the nature of these biased 
receptor conformations, particularly for the MOPr, is poorly understood. To this end, we 
performed molecular docking and molecular dynamics (MD) simulations
40
 to compare 
possible biased receptor conformations of the G protein-biased bilorphin versus β-arrestin-
biased endomorphin-2. Firstly, we analyzed the predicted binding poses of bilorphin and 
endomorphin-2 after 1 µs of MD simulation to determine if interactions with the MOPr 
binding pocket could differentiate these oppositely biased compounds. The binding pose of 
bilorphin is shown in Fig. 4A and SI Appendix Fig. S4A and that of endomorphin-2 in Fig. 
4B and SI Appendix Fig. S4B. There were similarities in how bilorphin and endomorphin-2 
interacted with the MOPr; both peptides bound in the orthosteric pocket with the phenol 
groups of the Dmt (bilorphin) or Tyr1 (endomorphin-2) orientated towards the intracellular 
side of MOPr, and maintained interactions with Asp147
3.32
,Trp293
6.48
 and His297
6.52
(Fig. 
4C). For the latter residue, bilorphin switched between a direct interaction and hydrogen 
bonding via a bridging water molecule (inset in Fig. 4A). However, there were also important 
differences in how these peptides interact with the MOPr binding pocket. For bilorphin, the 
rest of the tetrapeptide chain extended out towards the extracellular side of MOPr, making 
contacts with residues at the top of TMs 1, 2 and 7, resulting in bilorphin, but not 
endomorphin-2, interacting with Tyr75
1.39
 in TM1. Conversely, endomorphin-2 extended 
towards ECL1 and ECL2 and the top of TM2. Endomorphin-2 therefore interacted with the 
extracellular loops, contacting W133
ECL1
 in ECL1 for the entire simulation time, and 
transiently interacting with Cys217
ECL2
, Thr218
ECL2
 and Leu219
ECL2
 of ECL2. Whereas, these 
interactions were absent for bilorphin. Moreover, endomorphin-2 made a greater number of 
contacts with residues in TM3 and TM5 than bilorphin.  
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These predicted binding poses were validated by RMSD analysis showing stability of each 
ligand in the binding pocket, and our docking and MD protocol successfully recapitulated the 
binding pose of DAMGO when compared to the cryo-electron microscopy structure of the 
DAMGO-bound MOPr-Gi complex (see SI Appendix Fig. S5).
41
 
 
 
Next, principal component analysis was employed to examine the overall conformational 
changes in the receptor transmembrane helices in the presence of bilorphin or endomorphin-
2. The receptor conformations at each time point were projected onto principal components 
(PC) 1 and 2, and plotted in Fig. 4D. PC1 and PC2 accounted for 28.9 % and 10.9 % of the 
variance, respectively. Both peptide-MOPr complexes sampled conformations across PC2, 
but clustered differently based on PC1, suggesting that the MOPr adopted distinct 
conformations when bound to each biased agonist.  
 
As depicted in SI Appendix Fig. S4A,D, PC1 primarily described alternative conformations 
in the extracellular region of the receptor close to the orthosteric binding site, and to a lesser 
extent differences in the intracellular portions of the helices. With endomorphin-2 bound, 
there was an overall contraction of the orthosteric site, due to inward movements of TMs 2, 3, 
4 and 7. Whereas, with bilorphin bound, there was a bulging of the middle portion of TM1 
and a shift outwards from the helix bundle, relative to the endomorphin-2 bound receptor. 
These alternative conformations of the helices were also reflected in the volume of the 
orthosteric site, as with bilorphin bound the binding pocket volume was  on average 1.6 times 
greater than with endomorphin-2 bound
42
 (SI Appendix Fig. S4F).  On the intracellular side 
of MOPr, PC1 described inward movements of TMs 5, 6 and 7 with endomorphin-2 bound, 
compared to the bilorphin-bound MOPr (SI Appendix, Fig. S4F). The result was a more 
occluded intracellular cavity in the endomorphin-2-bound MOPr, compared to that with 
bilorphin bound.  
 
Analysis of the MD data therefore suggests that the different ligand-residue interactions for 
these oppositely biased peptides (with respect to the extracellular loops and TM1) may lead 
to the alternative receptor conformations described by the principal component analysis, and 
hence the opposing bias profiles of bilorphin and endomorphin-2.  
 
We then evaluated bilorphin in vivo. Bilorphin failed to inhibit nociception in the hotplate test 
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in mice when administered subcutaneously (100 mg/kg, n = 4) or intravenously (50 mg/kg n 
= 4). By contrast, bilorphin was antinociceptive after intrathecal injection (5 nmol/mouse, 
peak effect 41 ± 9 % MPE n = 4, versus 0 ± 1.5 % for vehicle, n = 4), suggesting the lack of 
systemic activity is due to poor penetration of the blood brain barrier (BBB). We therefore 
developed several bilorphin analogs with substitutions thought to enhance BBB permeability, 
including glycosylation near the C-terminus.
43
 The di-glycosylated analog, bilactorphin (3g), 
was a potent analgesic after systemic administration (s.c; ED50 of 34 µmol/kg, 95% CI = 28 - 
40 µmol/kg; SI Appendix Fig. S6A, B), was nearly equipotent with morphine (ED50 of 27 
µmol/kg, 95% CI = 24 - 30 µmol/kg SI Appendix Fig. S6B) and was antagonized by co-
administration of the opioid antagonist, naltrexone (SI Appendix Fig. S6A). Bilactorphin 
was also active after i.v. (peak effect of 88.9 ± 11.8 versus 14.4 ± 1.8 % MPE for vehicle, n = 
3-4) or oral administration (SI Appendix Fig. S7). In contrast, the mono-glycosylated analog 
3h was systemically inactive, consistent with previous modified opioid peptides.
43
 These 
findings establish that the natural LDLD opioid peptide backbone we have discovered is a 
viable framework for development of G-protein biased opioid analgesics. Like bilorphin, 
bilactorphin was a potent partial opioid agonist of G-proteins in AtT20 cells but exhibited a 
small loss of potency compared with bilorphin (SI Appendix Fig. S6C, D). Bilactorphin did, 
however, display increased internalization and β-arrestin recruitment compared to bilorphin 
(SI Appendix Fig. S6E, F) and thus might not be suitable for directly testing the role of bias 
in opioid side-effect profile. Alternative modifications that do not disrupt G-protein bias of 
the parent bilorphin might be better suited to enhance BBB permeability.  
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Discussion 
Nature has inspired many of the most well-known and widely used analgesics, from natural 
salicin in willow (Salix) bark to synthetic aspirin, from opioid poppy alkaloids such as 
morphine and codeine to synthetic hydrocodone (Vicodin), oxycodone (OxyContin) and 
buprenorphine (Subutex). Notwithstanding their value in alleviating pain, serious adverse 
side effects, combined with the challenge of addiction, abuse and acquired tolerance, render 
these analgesics (particularly opioids) far from ideal. There is an urgent need to discover and 
develop new, safer and more efficacious analgesics, with mechanisms of actions that mitigate 
against risk.  
 
We therefore investigated the analgesic potential of a novel class of tetrapeptides, the bilaids 
(1a-3a), isolated from a Penicillium fungus. Taking advantage of an unprecedented natural 
scaffold comprising alternating LDLD configuration amino acids, which imparts inherent 
biostability, we designed a new peptide-based G-protein biased MOPr agonist, bilorphin (3c). 
Furthermore, we assembled proof of concept data that this pharmacophore can be optimized 
to yield an orally active MOPr agonist analgesic, bilactorphin (3g).   
 
G-protein biased opioid agonists have been proposed as a route to improving therapeutic 
profile.
4,7,8
 Among known peptide opioid agonists, which typically are biased toward β-
arrestin signaling relative to morphine
19,34
, the pharmacological profile of bilorphin is most 
unusual, although a synthetic opioid cyclopeptide with G-protein bias was recently 
reported.
44
 Bilorphin enjoys an opioid signaling bias comparable to oliceridine, a G-protein 
biased drug candidate in Phase III clinical trials. Glycosylation of bilorphin produced an 
analog active in vivo via subcutaneous and oral administration, validating the bilorphin 
tetrapeptide backbone as a platform for further development of druggable signaling biased 
opioid agonists. Pre-clinical development of other G-protein biased agonists shows a 
favorable profile with reduced respiratory depression and constipation. The first such 
compound to reach clinical trials, oliceridine, was reported to have an increased therapeutic 
window between antinociceptive and respiratory depressive activity
7
 and appears to be safer 
in humans than morphine for equi-analgesic doses.
9
 Similarly, a series of substituted fentanyl 
analogs was observed to produce an increased therapeutic window for respiratory depression 
in mice, correlating with increased G-protein versus β-arrestin 2 recruitment.8 
 
To investigate whether bias could be explained by the differential interaction of bilorphin and 
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endomorphin-2 with MOPr, or by distinct receptor conformational changes initiated by each, 
we undertook MD simulations with bilorphin and compared this to the arrestin-biased opioid, 
endomorphin-2, bound to MOPr. Both peptides were docked to the orthosteric binding site of 
MOPr and displayed differences in ligand-residue interactions, which may translate to their 
differing bias profiles. Notably, endomorphin-2 transiently interacted with residues in ECL1 
and ECL2, including the conserved residue Leu219, proposed to be important for arrestin-
bias and ligand residence time at the 5-HT2A and 5-HT2B receptors and other aminergic 
GPCRs.
45,46
 The cryoEM-resolved structure of the DAMGO-MOPr-Gi complex also showed 
DAMGO, which robustly recruits arrestin, interacting with the receptor extracellular loops.
41
 
In contrast, bilorphin did not contact the extracellular loops, and instead interacted with TM1. 
Intriguingly, the extracellular end of TM1 has also been identified as part of the binding 
pocket for the G protein-biased GLP-1 agonist, ExP5
47
, and in addition has been implicated 
in the allosteric communication between the binding site and intracellular domain for 
oliceridine at the MOPr.
48
 Moreover, the interactions between the peptides and the MOPr 
binding pocket appear to translate to the divergent conformational changes observed by 
principal component analysis, resulting in the MOPr adopting a distinct conformation with 
bilorphin bound compared to endomorphin-2. Specifically, with bound endomorphin-2 the 
extracellular portions of the transmembrane domains moved inwards so that the orthosteric 
binding pocket contracted relative to the bilorphin-bound MOPr. On the intracellular side of 
the receptor TM5, 6 and 7 adopted distinct positions depending on the bound peptide, mainly 
an inward shift of these helices in the presence of endormorphin-2, resulting in a more 
occluded intracellular cavity for this arrestin-biased ligand. Of interest, this is in line with the 
proposed binding pocket for arrestins at the base of the GPCR being slightly smaller than 
those for G proteins.
59,50
  
 
Whilst it remains challenging at present to associate ligand-induced GPCR conformations 
with differential coupling to G-proteins or arrestins,2, particularly in the absence of a large 
structurally diverse panel of biased MOPr agonists, the subtle differences in ligand-residue 
interactions and conformations of the MOPr helices that we have modeled here may represent 
the initial changes induced by the oppositely biased peptides, bilorphin and endomorphin-2. 
These different interactions and MOPr conformations may well lead to the different 
signalling profiles reported for these biased peptide agonists at MOPr. 
 
It remains uncertain, however, whether G-protein bias per se is the sole property contributing 
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to the improved safety of new opioid drugs such as oliceridine.
9
 Using receptor knockdown, 
we have shown here that oliceridine has very low G-protein efficacy compared with 
morphine, similar to findings using receptor depletion with a cAMP assay system.
37
 Similar 
low efficacy results have recently been reported for another opioid, PZM21, also claimed to 
be safer than morphine.
53
 Furthermore, it is difficult to evaluate maximal G-protein efficacy 
of novel biased agonists in other studies because assays were insensitive to the relatively low 
G-protein efficacy of morphine.
7,8
 Very low G-protein efficacy may indeed be a confounding 
factor in the pre-clinical and clinical studies of side effect profile, given that other agonists 
with very low G-protein efficacy such as buprenorphine are not strongly G-protein biased
19
 
but are well characterized to produce less respiratory depression, and overdose death than 
highly efficacious agonists such as morphine and methadone.
54
 Because bilorphin is strongly 
G-protein biased and has nearly equivalent maximal G-protein efficacy to morphine, further 
development of BBB penetrant analogs that can release the parent molecule will facilitate 
direct test of the influence of bias without being confounded by differing G-protein efficacy. 
 
Finally, in addition to revealing a promising new analgesic pharmacophore, to the best of our 
knowledge the bilaid-bilorphin-bilactorphin motif is the first class of analgesic to be inspired 
from a microbial source. This observation suggests that microbes may be an untapped 
resource for new analgesics, deserving of further investigation. 
 
Experimental Procedures 
Full details on the materials and methods used are available in SI Appendix. Solvent extracts 
solid phase cultivations of MST-MF667 were subjected to solvent partition followed by 
reversed-phase HPLC and chemical structures were identified on the basis of detailed 
spectroscopic analysis, chemical derivatization and degradation, Marfey's analysis and total 
synthesis. All peptides were assembled manually by stepwise solid-phase peptide synthesis. 
MOPr activity was initially screened using competition opioid radioligand binding to 
membranes  from cultured cells expressing hMOPr, hDOPr or hKOPr receptors, then agonist 
activity screened at hMOPr using inhibition of forskolin-stimmulated cAMP formation. 
Agonist activation of MOPr coupled GIRK channels was then quantified using superfusion 
onto LC neurons in rate brain slices using whole cell patch clamp recording. Signaling 
pathway analysis was quantified in AtT20 cells stably expressing mMOPr using perforated 
patch recording for GIRK channels activation (G-protein signal), fluorescence 
immunohistochemistry for Ser375 phosphorylation and MOPr internalization and arrestin 
 13 
 
recruitment with a bioluminescence resonance energy transfer (BRET)-based approach. 
Molecular docking was performed using the Bristol University Docking Engine (BUDE).
55
 
The selected peptide-MOPr complexes were then embedded in a lipid and cholesterol bilayer 
and used in all-atom MD simulations. 8 x 125 ns simulations, with different initial velocities, 
were performed under the Amber ff14SB and Lipid14 forcefields, to yield a total of 1 μs of 
trajectory data for each peptide. Behavioural assays of analgesia were performed using the 
hotplate latency assay in mice. Statistical analyses were performed as described in SI 
Appendix. All values are expressed as means ± SEM, except where noted otherwise (SI 
Appendix, Fig. S2). 
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Figure 1.  
Structures of bilaids, bilorphin and bilactorphin. 
 
Figure 2 
Competition for binding of [
3
H]DAMGO to hMOPr (human recombinant MOPr) by the 
native bilaid YvVf-OH (3a), YvVf-NH2 (3b) and bilorphin ([Dmt]vVf-NH2) (3c), as well as 
bilorphin to hDOPr ([
3
H]DADLE binding to human recombinant DOPr) and hKOPr ([
3
H] 
U69593 binding to human recombinant KOPr). B. Exemplar GIRK current recorded from a 
rat LC neuron in response to Met-enk (Met-enk; 1 µM), bilorphin (1µM) applied for duration 
of bars shown, and its reversal by co-application of the MOPr selective antagonist, CTAP (D-
Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2, 1µM). Scale bars: 50 pA, 5 min. C. Exemplar 
record of bilorphin, morphine and Met-enk-induced GGIRK in mMOPr-expressing AtT20 cells 
in response to somatostatin (SST) and opioids after alkylation of a fraction of receptors by the 
irreversible MOPr antagonist β-chlornaltrexamine (β-CNA). Scale bar 0.2 nS, 1 min D. 
Agonist concentration-response relationships of opioids for activation of GIRK current in LC 
neurons normalized to 1 µM Met-enk applied first as a reference in each cell (N = 4-13 cells 
per data point; endo-2 = endomorphin-2).  E. Concentration-response curves of GGIRK 
induced by opioids in AtT20 cells after reducing the receptor reserve. 
 
 
Figure 3 
 A. Representative images of S375 phosphorylation in AtT20 cells induced by saturating 
concentrations (30 µM) of Met-enk, endomorphin-2, morphine and bilorphin after 5 min 
incubation. Colors enhanced uniformly for all panels for presentation purposes. B. Time 
course of ligand-induced BRET signal (ratio of emission of 535 nm / 475 nm, baseline 
subtracted) indicating β-arrestin 2 recruitment after incubation with saturating concentrations 
of agonists (shown by the arrow). The band represents the standard error of experiments 
repeated independently 6 times (each experiment in triplicate). C. Example images of MOPr 
internalization 30 min after incubation with saturating concentrations of agonists. Dual 
staining was employed for quantification (membrane receptor in green and internalized 
receptor in red, colors enhanced uniformly for presentation purposes). D. Maximal efficacy 
values of endomorphin-2, morphine and bilorphin relative to Met-enk for GIRK channel 
activation, Ser375 phosphorylation, β-arrestin 2 recruitment and internalization (all 
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normalized to met-enk; non-normalized data in SI Appendix Fig. S2).  
 
 
Figure 4  
 
A. Predicted binding poses of bilorphin (purple), and B. endomorphin-2 (orange), and the 
positions of the surrounding binding pocket residues (grey) obtained after molecular docking 
and 1 μs of MD simulations. The salt bridge between the protonated amine of the ligands and 
Asp147
3.32 
is marked as a dashed black line. TM7 has been removed for clarity. C. Ligand - 
residue interaction fingerprints for the bilorphin – MOPr complex (purple) and endomorphin2 
– MOPr complex (orange). Data is expressed as the percentage of simulation time each 
residue is within 4.5 Å of the ligand, with points radiating outwards from 0 % to 100 % in 20 
% increments. D. Principal component analysis was performed on the alpha carbons of the 
receptor transmembrane domains, before projecting the receptor conformations at each 
simulation time point onto PC1 and PC2. The bilorphin – MOPr complex is in purple, the 
endomorphin-2 – MOPr complex in orange, and the black point indicates the conformation of 
the inactive MOPr model to which the peptides were docked. 
 
